STALICLA is a clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders. STALICLA is on a unique mission to identify clinically actionable patient subgroups and develop treatments for those most impaired by their symptoms. Its DEPI technology is the first platform developed to enable precision medicine in NDDs. It integrates comprehensive metabolomics, whole-genome sequencing, RNA-sequencing data and its HC-Match module to pair patient biological signatures with drug candidates. DEPI has reached clinical proof-of-concept with its first pipeline candidate, currently in clinical trials. STALICLA will also bring two additional pipelines to the clinic in 2022.